Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.


Journal

The American journal of psychiatry
ISSN: 1535-7228
Titre abrégé: Am J Psychiatry
Pays: United States
ID NLM: 0370512

Informations de publication

Date de publication:
01 04 2019
Historique:
pubmed: 16 2 2019
medline: 18 12 2019
entrez: 16 2 2019
Statut: ppublish

Résumé

Adults with major depressive disorder frequently do not achieve remission with an initial treatment. Addition of psychotherapy for patients who do not achieve remission with antidepressant medication alone can target residual symptoms and protect against recurrence, but the utility of adding antidepressant medication after nonremission with cognitive-behavioral therapy (CBT) has received little study. The authors aimed to evaluate the acute and long-term outcomes resulting from both sequences of combination treatments. Previously untreated adults with major depression who were randomly assigned to receive escitalopram, duloxetine, or CBT monotherapy and completed 12 weeks of treatment without achieving remission entered an additional 12 weeks of combination treatment. For patients who did not achieve remission with CBT, escitalopram was added (CBT plus medication group) to their treatment, and for those who did not achieve remission with an antidepressant, CBT was added (medication plus CBT group) to their treatment. Patients who responded to the combination treatment entered an 18-month follow-up phase to assess risk of recurrence. A total of 112 patients who did not achieve remission with a monotherapy entered combination treatment (41 who responded to monotherapy but did not achieve remission and 71 who did not respond to monotherapy). Overall, remission rates after subsequent combination therapy were significantly higher among patients who responded to monotherapy but did not achieve remission (61%) than among patients who did not respond to monotherapy (41%). Among patients who responded to monotherapy but did not achieve remission, the remission rate in the CBT plus medication group (89%) was higher than in the medication plus CBT group (53%). However, among patients whose depression did not respond to monotherapy, rates of response and remission were similar between the treatment arms. Higher levels of anxiety, both prior to monotherapy and prior to beginning combination treatment, predicted poorer outcomes for both treatment groups. The order in which CBT and antidepressant medication were sequentially combined did not appear to affect outcomes. Addition of an antidepressant is an effective approach to treating residual symptoms for patients who do not achieve remission with CBT, as is adding CBT after antidepressant monotherapy. Patients who do not respond to one treatment modality warrant consideration for addition of the alternative modality.

Identifiants

pubmed: 30764648
doi: 10.1176/appi.ajp.2018.18091075
pmc: PMC6557125
mid: NIHMS1525256
doi:

Substances chimiques

Antidepressive Agents 0
Citalopram 0DHU5B8D6V
Duloxetine Hydrochloride 9044SC542W

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

275-286

Subventions

Organisme : NCRR NIH HHS
ID : M01 RR000039
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH080880
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH086690
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH077083
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025008
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Arch Gen Psychiatry. 2005 Apr;62(4):409-16
pubmed: 15809408
World Psychiatry. 2014 Feb;13(1):56-67
pubmed: 24497254
J Clin Psychiatry. 2010 Aug;71(8):1047-54
pubmed: 20673545
Am J Psychiatry. 2017 Jun 1;174(6):546-556
pubmed: 28335624
Psychopharmacol Bull. 1987;23(2):309-24
pubmed: 3303100
Br J Med Psychol. 1959;32(1):50-5
pubmed: 13638508
Focus (Am Psychiatr Publ). 2016 Apr;14(2):156-173
pubmed: 31975799
Psychother Psychosom. 2015 Feb 21;84(2):72-81
pubmed: 25721705
Can J Psychiatry. 2016 Sep;61(9):524-39
pubmed: 27486150
J Consult Clin Psychol. 2007 Apr;75(2):344-50
pubmed: 17469892
JAMA. 2010 Jan 6;303(1):47-53
pubmed: 20051569
JAMA Psychiatry. 2015 Nov;72(11):1102-9
pubmed: 26397232
Trials. 2012 Jul 09;13:106
pubmed: 22776534
Am J Psychiatry. 2016 Feb 1;173(2):128-37
pubmed: 26481173
JAMA Psychiatry. 2013 Aug;70(8):821-9
pubmed: 23760393
Arch Gen Psychiatry. 1987 Jun;44(6):540-8
pubmed: 3579500
Am J Psychiatry. 2008 Mar;165(3):342-51
pubmed: 18172020
Depress Anxiety. 2010;27(1):12-8
pubmed: 20013987
J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):237-9
pubmed: 26067435
Arch Gen Psychiatry. 2009 Nov;66(11):1178-88
pubmed: 19884606
Am J Psychiatry. 1991 Aug;148(8):997-1008
pubmed: 1853989
Am J Psychiatry. 2007 May;164(5):739-52
pubmed: 17475733
JAMA Psychiatry. 2013 Nov;70(11):1152-60
pubmed: 24005123
Psychother Psychosom. 2013;82(2):89-98
pubmed: 23295630
J Consult Clin Psychol. 2009 Aug;77(4):775-87
pubmed: 19634969
Eur Psychiatry. 2010 Jan;25(1):58-65
pubmed: 19553092
Psychother Psychosom. 2018;87(5):257-267
pubmed: 30149374
Psychol Med. 2010 Jan;40(1):41-50
pubmed: 19460188
Annu Rev Psychol. 2014;65:267-300
pubmed: 24405361
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
pubmed: 6080235
J Clin Psychiatry. 2013 Jun;74(6):595-602
pubmed: 23842011
Psychotherapy (Chic). 2015 Jun;52(2):268-77
pubmed: 25985046
Am J Psychiatry. 2017 Jun 1;174(6):533-545
pubmed: 28335622
PLoS One. 2014 Jan 08;9(1):e83875
pubmed: 24416178
J Clin Psychiatry. 2011 Apr;72(4):509-14
pubmed: 21527126
JAMA Psychiatry. 2016 Jun 1;73(6):565-74
pubmed: 27119968
BMJ Open. 2013 Apr 26;3(4):
pubmed: 23624992
Clin Psychol Rev. 2014 Aug;34(6):506-17
pubmed: 25189522
Eur Arch Psychiatry Clin Neurosci. 2011 Apr;261(3):147-56
pubmed: 20859636
J Consult Clin Psychol. 2007 Jun;75(3):475-88
pubmed: 17563164
J Clin Psychol. 2009 Apr;65(4):368-81
pubmed: 19226606
Compr Psychiatry. 2007 Mar-Apr;48(2):113-7
pubmed: 17292700
J Psychiatr Res. 2012 Mar;46(3):375-81
pubmed: 22118808
Arch Gen Psychiatry. 2005 May;62(5):513-20
pubmed: 15867104
J Clin Psychiatry. 2009 Mar;70(3):354-61
pubmed: 19192474
Psychother Psychosom. 2018;87(4):195-203
pubmed: 30016772
J Psychiatry Neurosci. 2002 Jul;27(4):281-90
pubmed: 12174737
J Clin Psychiatry. 2000 Jan;61(1):51-7
pubmed: 10695647
JAMA Psychiatry. 2013 Nov;70(11):1241-7
pubmed: 24048258
Dialogues Clin Neurosci. 2015 Jun;17(2):111-26
pubmed: 26246787
J Consult Clin Psychol. 2018 Feb;86(2):189-199
pubmed: 29369664
Int J Clin Pract. 2006 May;60(5):613-20
pubmed: 16700869
Arch Gen Psychiatry. 2012 Jun;69(6):572-9
pubmed: 22393205
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
Psychother Psychosom. 2018;87(3):140-153
pubmed: 29847831

Auteurs

Boadie W Dunlop (BW)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Devon LoParo (D)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Becky Kinkead (B)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Tanja Mletzko-Crowe (T)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Steven P Cole (SP)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Charles B Nemeroff (CB)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Helen S Mayberg (HS)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

W Edward Craighead (WE)

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH